# US 2004/0204562 A1 · Polynucleotides encoding cytokine receptor zalpha11

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204562 A1
- Document ID: US20040204562A1
- Status: Published application
- Kind: A1
- Application number: 10/715,998
- Filed: 2003-11-18
- Published: 2004-10-14
- Earliest claimed: 2003-04-14
- Assignees: ZymoGenetics, Inc.
- Inventors: Scott R. Presnell; Darrell C. Conklin; Julia E. Novak; Angela K. Hammond
- Web page: https://patentgrep.com/patent/US20040204562A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 16/1232: Escherichia (G)
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2319/00: Fusion polypeptide
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

## Claims

### Claim 1

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues selected from the group consisting of:
(a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His);
(b) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 255 (Leu);
(c) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 256 (Lys), to amino acid number 538 (Ser);
(d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Ser); and
(e) polynucleotide sequences complementary to the polynucleotides encoding the polypeptides consisting of a sequence of amino acid residues as shown in (a), (b), (c), and (d).

### Claim 2

An isolated polynucleotide encoding a polypeptide consisting of an amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His), and wherein the polypeptide further comprises a biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

### Claim 3

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues selected from the group consisting of:
(a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His);
(b) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 255 (Leu);
(c) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Ser); and
wherein the polypeptide further comprises an affinity tag, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain; and
wherein the polypeptide exhibits cell proliferation activity when exposed to activated CD3+ selected human T-cell conditioned media.

### Claim 4

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His); and
wherein the polypeptide further comprises an affinity tag, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain; and
wherein the polypeptide competitively inhibits cell proliferation activity of cells expressing a polypeptide comprising amino acids 20 (Cys) to amino acid number 538 (Ser) of SEQ ID NO:2 when exposed to activated CD3+ selected human T-cell conditioned media.

### Claim 5

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid number 256 (Lys) to amino acid number 538 (Ser); and
wherein the polypeptide further comprises an affinity tag, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain; and
wherein the polypeptide has signal transduction activity.

### Claim 6 (depends on 1)

The isolated polynucleotide encoding a polypeptide according to claim 1, wherein the polypeptide comprises a WSXWS motif as shown in SEQ ID NO:3.

### Claim 7 (depends on 1)

The isolated polynucleotide encoding a polypeptide according to claim 1, wherein the polypeptide comprises a transmembrane domain.

### Claim 8 (depends on 1)

The isolated polynucleotide encoding a polypeptide according to claim 1, wherein the transmembrane domain consists of residues 238 (Leu) to 255 (Leu) of SEQ ID NO:2.

### Claim 9 (depends on 1)

The isolated polynucleotide encoding a polypeptide according to claim 1, wherein the polypeptide comprises an intracellular domain.

### Claim 10 (depends on 9)

The isolated polynucleotide encoding a polypeptide according to claim 9, wherein the intracellular domain comprises residues 256 (Lys) to 538 (Ser) of SEQ ID NO:2.

### Claim 11 (depends on 9)

The isolated polynucleotide encoding a polypeptide according to claim 9 wherein the intracellular domain further comprises residues 267 (Ile) to 273 (Pro) and 301 (Leu) to 304 (Gly) of SEQ ID NO:2.

### Claim 12

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues selected from the group consisting of:
(a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His);
(b) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 255 (Leu);
(c) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 256 (Lys), to amino acid number 538 (Ser);
(d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Ser); and
wherein the polypeptide further comprises an affinity tag, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

### Claim 13

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His), and wherein the polypeptide further comprises a transmembrane from a heterologous cytokine receptor.

### Claim 14 (depends on 13)

The isolated polynucleotide encoding a polypeptide according to claim 13, wherein the heterologous cytokine receptor is a class I cytokine receptor.

### Claim 15

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His), and wherein the polypeptide further comprises a transmembrane domain and an intracellular domain from a heterologous cytokine receptor.

### Claim 16 (depends on 15)

The isolated polynucleotide encoding a polypeptide according to claim 15, wherein the heterologous cytokine receptor is a class I cytokine receptor.

### Claim 17

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 255 (Leu), and wherein the polypeptide further comprises an intracellular domain from a heterologous cytokine receptor.

### Claim 18 (depends on 17)

The isolated polynucleotide encoding a polypeptide according to claim 17, wherein the heterologous cytokine receptor is a class I cytokine receptor.

### Claim 19

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid number 256 (Lys), to amino acid number 538 (Leu), and wherein the polypeptide further comprises a transmembrane domain and a cytokine binding domain from a heterologous cytokine receptor.

### Claim 20 (depends on 19)

The isolated polynucleotide encoding a polypeptide according to claim 19, wherein the heterologous cytokine receptor is a class I cytokine receptor.

### Claim 21

An isolated polynucleotide encoding a polypeptide consisting of a sequence of amino acid residues as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Leu).

### Claim 22

An isolated polynucleotide comprising a sequence of polynucleotides selected from the group consisting of:
(a) a polynucleotide sequence as shown in SEQ ID NO: 1;
(b) a polynucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 1 to nucleotide 1682;
(c) a polynucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 1 to nucleotide 779;
(d) a polynucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 1 to nucleotide 833;
(e) a polynucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 126 to nucleotide 2887;
(f) a polynucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 834 to nucleotide 2887; and
(g) polynucleotide sequences complementary to (a), (b) (c), (d), (e), and (f).

### Claim 23 (depends on 22)

The isolated polynucleotide according to claim 22, wherein the polynucleotide consists of a sequence of polynucleotides selected from the group consisting of:
(a) a polynucleotide sequence as shown in SEQ ID NO: 1;
(b) a polynucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 1 to nucleotide 1682;
(c) a polynucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 1 to nucleotide 779;
(d) a polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 1 to nucleotide 833;
(e) a polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 126 to nucleotide 2887;
(f) a polynucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 834 to nucleotide 2887; and
(g) polynucleotide sequences complementary to (a), (b) (c), (d), (e), and (f).

### Claim 24

An isolated polynucleotide consisting of a sequence of polynucleotides that is selected from the group consisting of:
(a) a polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 126 to nucleotide 779;
(b) a polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 126 to nucleotide 833;
(c) a polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 834 to nucleotide 1682;
(d) a polynucleotide sequence as shown in SEQ ID NO:1 from nucleotide 126 to nucleotide 1682; and
(g) polynucleotide sequences complementary to (a), (b) (c),and (d).

### Claim 25

An expression vector comprising the following operably linked elements:
a transcription promoter;
a DNA segment encoding a polypeptide consisting of an amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Ser); and
a transcription terminator,
wherein the promoter is operably linked to the DNA segment, and the DNA segment is operably linked to the transcription terminator.

### Claim 26 (depends on 25)

The expression vector according to claim 25, further comprising a secretory signal sequence operably linked to the DNA segment.

### Claim 27 (depends on 25)

A cultured cell comprising an expression vector according to claim 25, wherein the cell expresses a polypeptide encoded by the DNA segment.

### Claim 28 (depends on 27)

The cell according to claim 27, wherein the cell is dependent upon an exogenously supplied hematopoietic growth factor for proliferation.

### Claim 29 (depends on 28)

The cell according to claim 28, wherein the hematopoietic growth factor is present in activated CD3+ selected human T-cell conditioned media

### Claim 30

An expression vector comprising:
a transcription promoter;
a DNA segment encoding a polypeptide consisting of an amino acid sequence as shown in SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 237 (His); and
a transcription terminator,
wherein the promoter, DNA segment, and terminator are operably linked.

### Claim 31 (depends on 30)

The expression vector according to claim 30, further comprising a secretory signal sequence operably linked to the DNA segment.

### Claim 32 (depends on 30)

The expression vector according to claim 30, wherein the polypeptide further comprises a transmembrane from a heterologous cytokine receptor operably linked to the DNA segment.

### Claim 33 (depends on 32)

The expression vector according to claim 32, wherein the heterologous cytokine receptor is a class I cytokine receptor.

### Claim 34 (depends on 30)

The expression vector according to claim 30, wherein the polypeptide further comprises a transmembrane domain and an intracellular domain from a heterologous cytokine receptor.

### Claim 35 (depends on 34)

The expression vector according to claim 34, wherein the heterologous cytokine receptor is a class I cytokine receptor.

### Claim 36 (depends on 30)

A cultured cell into which has been introduced an expression vector according to claim 30, wherein the cell expresses a soluble receptor polypeptide encoded by the DNA segment.

### Claim 37 (depends on 36)

The cell according to claim 36, wherein the cell is dependent upon an exogenously supplied hematopoietic growth factor for proliferation.

### Claim 38 (depends on 37)

The cell according to claim 37, wherein the hematopoietic growth factor is present in activated CD3+ selected human T-cell conditioned media.

### Claim 39

A DNA construct encoding a fusion protein, the DNA construct comprising:
a first DNA segment encoding a polypeptide consisting of a sequence of amino acid residues selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:2 from amino acid number 1 (Met), to amino acid number 19 (Gly);
(b) the amino acid sequence of SEQ ID NO:2 from amino acid number 20 (Cys) to amino acid number 237 (His);
(c) the amino acid sequence of SEQ ID NO:2 from amino acid number 20 (Cys) to amino acid number 255 (Leu);
(d) the amino acid sequence of SEQ ID NO:2 from amino acid number 238 (Leu) to amino acid number 255 (Leu);
(e) the amino acid sequence of SEQ ID NO:2 from amino acid number 238 (Leu) to amino acid number 538 (Ser);
(f) the amino acid sequence of SEQ ID NO:2 from amino acid number 256 (Lys) to amino acid number 538 (Ser); and
(g) the amino acid sequence of SEQ ID NO:2 from amino acid number 20 (Cys), to amino acid number 538 (Ser); and
at least one other DNA segment encoding an additional polypeptide,
wherein the first and other DNA segments are connected in-frame; and
wherein the first and other DNA segments encode the fusion protein.

### Claim 40 (depends on 39)

An expression vector comprising the following operably linked elements:
a transcription promoter;
a DNA construct encoding a fusion protein according to claim 39; and
a transcription terminator,
wherein the promoter is operably linked to the DNA construct, and the DNA construct is operably linked to the transcription terminator.

### Claim 41 (depends on 40)

A cultured cell comprising an expression vector according to claim 40, wherein the cell expresses a polypeptide encoded by the DNA construct.

### Claim 42 (depends on 41)

A method of producing a fusion protein comprising:
culturing a cell according to claim 41; and
isolating the polypeptide produced by the cell.

### Claim 43 (depends on 25)

A method of producing a polypeptide comprising:
culturing a cell according to claim 25; and
isolating the polypeptide produced by the cell.

### Claim 44 (depends on 30)

A method of producing a polypeptide comprising:
culturing a cell according to claim 30; and
isolating the polypeptide produced by the cell.

### Claim 45 (depends on 36)

A method of producing a polypeptide comprising:
culturing a cell according to claim 36; and
isolating the polypeptide produced by the cell.
